SCHEMBL6217339

SCHEMBL6217339

OCC(O)CC1OCCO1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
THRB P10828 1/20 0.33
MAPT P10636 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6578925 1.00 LMNA (0.40) LMNAALDH1A1THRBMAPTATM
SCHEMBL9529967 0.76
SCHEMBL3386110 0.74
SCHEMBL6836741 0.73 CHRM2 (0.41) LMNAALDH1A1
Oxirane SCHEMBL11531139 0.73 ALDH1A1 (0.35) LMNAALDH1A1
SCHEMBL11237163 0.70
SCHEMBL6419144 0.70 USP2 (0.41) LMNAALDH1A1MAPT
SCHEMBL11681867 0.70
Glycerin SCHEMBL830352 0.67
Glycerin SCHEMBL3943790 0.67 LMNA (0.64) LMNAALDH1A1THRBMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1216053-C 2,2-disubstituted 1,3,-dioxolanes as antitussive agents DOMPE SPA (IT) 2005-08-24 CN claimed
US-6916926-B2 Process for the preparation of (±) 1-3-dioxolanes and the optical resolution thereof DOMPE S.P.A. (IT) 2005-07-12 US claimed
CN-1204135-C 1, 3-dioxolanes with antitussive activity DOMPE SPA (IT) 2005-06-01 CN claimed
EP-1307440-B1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS DOMPE SPA (IT) 2005-03-09 EP claimed
CN-1444579-A 2, 2-disubstituted 1, 3-dioxolanes as antitussives DOMPE SPA (IT) 2003-09-24 CN claimed
CN-1444578-A 1, 3-dioxolanes with antitussive activity DOMPE SPA (IT) 2003-09-24 CN claimed
US-20030176446-A1 2,2-disubstituted 1,3-dioxolanes as antitussive agents DOMPÉ FARMACEUTICI S.P.A. (IT) 2003-09-18 US claimed
EP-1307440-A1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS Dompe' S.P.A. (IT) 2003-05-07 EP claimed
WO-2002010150-A1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS DOMPE' S.P.A. (IT) 2002-02-07 WO claimed
CN-1216053-C 2,2-disubstituted 1,3,-dioxolanes as antitussive agents DOMPE SPA (IT) 2005-08-24 CN disclosed
US-6916926-B2 Process for the preparation of (±) 1-3-dioxolanes and the optical resolution thereof DOMPE S.P.A. (IT) 2005-07-12 US disclosed
CN-1204135-C 1, 3-dioxolanes with antitussive activity DOMPE SPA (IT) 2005-06-01 CN disclosed
EP-1307440-B1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS DOMPE SPA (IT) 2005-03-09 EP disclosed
US-6835734-B2 (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, useful as intermediates for the preparation of levodropropizine Dompé S.p.A. (IT) 2004-12-28 US disclosed
CN-1444578-A 1, 3-dioxolanes with antitussive activity DOMPE SPA (IT) 2003-09-24 CN disclosed
US-20030176446-A1 2,2-disubstituted 1,3-dioxolanes as antitussive agents DOMPÉ FARMACEUTICI S.P.A. (IT) 2003-09-18 US disclosed
EP-1307440-A1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS Dompe' S.P.A. (IT) 2003-05-07 EP disclosed
EP-1307441-A1 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY Dompe' S.P.A. (IT) 2003-05-07 EP disclosed
WO-2002010150-A1 2,2-DISUBSTITUTED 1,3-DIOXOLANES AS ANTITUSSIVE AGENTS DOMPE' S.P.A. (IT) 2002-02-07 WO disclosed
WO-2002010149-A1 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY DOMPE' S.P.A. (IT) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176446-A1 2,2-disubstituted 1,3-dioxolanes as antitussive agents ADRB2, QDPR, ADRB3 LMNA 3401/4885ALDH1A1 295/4885THRB 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.